MRI screening may identify high-risk pancreatic cancer

Share this content:

the ONA take:

MRI-based screening may be effective in identifying high-risk pancreatic cancer, according to a recent study published in JAMA Surgery.

Researchers led by Marco Del Chiaro, MD, PhD, of the Karolinska Institute in Stockholm looked at 40 patients (24 women, 16 men) who were at genetic risk of developing pancreatic cancer in order to determine short-term results of a MRI-based screening program.

Median follow-up was 12.9 months, and MRI screening was repeated after one year if initial screening was negative or at six months if findings were unspecific.

The researchers were able to find pancreatic lesions in 16 patients – 40 percent – with 14 who had intraductal papillary mucinous neoplasia and two who had pancreatic ductal adenocarcinoma.

“An MRI-based protocol for the surveillance of individuals at risk for developing pancreatic cancer seems to detect cancer or premalignant lesions with good accuracy,” the authors concluded. “The exclusive use of MRI can reduce costs, increase availability and guarantee the safety of the individuals under surveillance compared with protocols that are based on more aggressive methods.”

However, the authors emphasize that their study did not allow for evaluation of efficacy as single-screening modality, due to the small patient sample.

MRI has high sensitivity for the early detection of marrow infiltration by myeloma cells.
MRI-based screening may be effective in identifying high-risk pancreatic cancer.
A magnetic resonance imaging (MRI)-based screening program for individuals at high risk of pancreatic cancer identified pancreatic lesions in 16 of 40 (40 percent) of patients, of whom 5 five underwent surgery, according to a report published online by JAMA Surgery.
READ FULL ARTICLE From Medical Express
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs